Realtime-Chart: http://de.advfn.com/p.php?pid=staticchart&s=N%5EXOMA&p=0&t=16... http://www.xoma.com Surprise on the horizon ? to build up positions.... BERKELEY, Calif., March 16, 2009 (GLOBE NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced today that Steven Engle, Chairman and Chief Executive Officer of XOMA, is scheduled to present at the Cowen and Company Health Care Conference. The presentation will take place in Boston on Wednesday, March 18, at 9:30 A.M. Eastern time. An audio webcast of the presentation will be available live at http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=XOMA... An archived version of the webcast will be available for 90 days following the presentation. About XOMA XOMA discovers, develops and manufactures therapeutic antibody and other agents designed to treat inflammatory, autoimmune, infectious and cancerous diseases. The company's proprietary product pipeline includes XOMA 052, an anti-IL-1 beta antibody, and XOMA 3AB, a biodefense anti-botulism antibody candidate. XOMA's proprietary development pipeline is primarily funded by multiple revenue streams resulting from the licensing of its antibody technologies, product royalties, development collaborations and biodefense contracts. XOMA's technologies and experienced team have contributed to the success of marketed antibody products, including RAPTIVA(r) (efalizumab) for chronic moderate to severe plaque psoriasis, LUCENTIS(r) (ranibizumab injection) for wet age-related macular degeneration and CIMZIA(r) (certolizumab pegol) for Crohn's disease. The company has a premier antibody discovery and development platform that incorporates leading antibody phage display libraries and XOMA's proprietary Human Engineering(tm) and Bacterial Cell Expression and manufacturing technologies. Bacterial Cell Expression is a key breakthrough biotechnology for the discovery and manufacturing of antibodies and other proteins. As a result, more than 50 pharmaceutical and biotechnology companies have signed BCE licenses. In addition to developing its own products, XOMA develops products with premier pharmaceutical companies including Novartis AG, Schering-Plough Research Institute and Takeda Pharmaceutical Company Limited. XOMA has a fully integrated product development infrastructure, extending from pre-clinical science to approval, and a team of about 200 employees at its Berkeley location. For more information, please visit: http://www.xoma.com Y M
$0.417 (03/19/09)
